Is the GABAB Heterodimer a Good Drug Target?
- 1 January 2005
- journal article
- review article
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 26 (2-3) , 169-176
- https://doi.org/10.1385/jmn:26:2-3:169
Abstract
GABAB receptors are a member of the G protein-coupled family of receptors which are generally considered to be excellent drug targets. Cloning of the GABAB receptor demonstrated that, unlike other G protein-coupled receptors, it is an obligate heterodimer. Drugs acting at GABAB receptors have the potential to treat a wide variety of diseases. Activation of the receptors may have utility in the treatment of pain, drug-dependence, and anxiety, whereas blockade of receptors may have benefit in cognitive disorders and depression. To date, development of drugs has been hampered by the lack of receptor subtypes and the inability to separate therapeutic benefit from side effects such as sedation. Recently, novel compounds that act via an allosteric mechanism have been identified and are providing hope that future drugs may be developed that target this receptor.Keywords
This publication has 49 references indexed in Scilit:
- Cocaine alters GABAB-mediated G-protein activation in the ventral tegmental area of female rats: Modulation by estrogenSynapse, 2004
- Hetero-oligomerization between GABAA and GABAB Receptors Regulates GABAB Receptor TraffickingPublished by Elsevier ,2004
- Molecular Determinants Involved in the Allosteric Control of Agonist Affinity in the GABAB Receptor by the GABAB2 SubunitPublished by Elsevier ,2004
- Epilepsy, Hyperalgesia, Impaired Memory, and Loss of Pre- and Postsynaptic GABAB Responses in Mice Lacking GABAB(1)Neuron, 2001
- Epileptogenesis and Enhanced Prepulse Inhibition in GABAB1-Deficient MiceMolecular and Cellular Neuroscience, 2001
- GABAB-receptor isoforms: Molecular architecture and distributionLife Sciences, 2001
- Cloning and functional expression of GABAB receptors from DrosophilaEuropean Journal of Neuroscience, 2001
- Multiple GABAB receptorsTrends in Pharmacological Sciences, 1993
- CGP 36742: The first orally active GABAB blocker improves the cognitive performance of mice, rats, and rhesus monkeysBehavioral and Neural Biology, 1993
- (–)Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptorNature, 1980